ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · Real-Time Price · USD
21.98
+0.64 (3.00%)
At close: Jun 6, 2025, 4:00 PM
21.75
-0.23 (-1.05%)
After-hours: Jun 6, 2025, 5:06 PM EDT
3.00%
Market Cap 3.68B
Revenue (ttm) 996.28M
Net Income (ttm) 228.88M
Shares Out 167.36M
EPS (ttm) 1.37
PE Ratio 16.06
Forward PE 46.37
Dividend n/a
Ex-Dividend Date n/a
Volume 1,280,062
Open 21.53
Previous Close 21.34
Day's Range 21.47 - 22.10
52-Week Range 13.40 - 25.23
Beta 0.65
Analysts Buy
Price Target 27.00 (+22.84%)
Earnings Date Aug 5, 2025

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2004
Employees 654
Stock Exchange NASDAQ
Ticker Symbol ACAD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $27.0, which is an increase of 22.84% from the latest price.

Price Target
$27.0
(22.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June...

2 days ago - Business Wire

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Mond...

8 days ago - Business Wire

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role All...

10 days ago - Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted induceme...

17 days ago - Business Wire

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday.

19 days ago - Benzinga

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Acadia Pharmaceuticals secured another court win on Nuplazid that solidifies its IP position and long-term exclusivity. The commercial business' performance remains slightly underwhelming but there ar...

21 days ago - Seeking Alpha

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation...

21 days ago - Business Wire

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updat...

25 days ago - Seeking Alpha

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom...

4 weeks ago - Seeking Alpha

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start for Acadia, achi...

4 weeks ago - Business Wire

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13...

4 weeks ago - Business Wire

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financ...

6 weeks ago - Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: M...

3 months ago - Business Wire

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability ...

3 months ago - Business Wire

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

SAN DIEGO & COPENHAGEN, Denmark--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts i...

3 months ago - Business Wire

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

ACADIA Pharmaceuticals reported its fourth quarter results this week and provided initial guidance for FY2025, highlighting key financial metrics and future projections. The company continues to see s...

3 months ago - Seeking Alpha

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March ...

3 months ago - Business Wire

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine...

3 months ago - Seeking Alpha

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a strong n...

3 months ago - Business Wire

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after th...

4 months ago - Business Wire

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discu...

5 months ago - Business Wire

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)...

5 months ago - Business Wire

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Ad...

6 months ago - Business Wire

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees ...

6 months ago - Business Wire

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead...

6 months ago - Business Wire